Nintedanib (BIBF 1120) for IPF: a tomorrow therapy?
<p>Abstract</p> <p>Idiopathic pulmonary fibrosis is a rare, life threatening disease characterized by an anarchic fibrogenesis, limited survival and few therapeutic options. Its pathogenesis is complex and involves the interaction among various pathways driven by proinflammatory/pr...
Main Author: | Antoniu Sabina A |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2012-11-01
|
Series: | Multidisciplinary Respiratory Medicine |
Subjects: | |
Online Access: | http://www.mrmjournal.com/content/7/1/41 |
Similar Items
-
Effect of a novel tyrosine kinase inhibitor nintedanib on bFGF and VEGF concentrations in a rabbit retinal vein occlusion model
by: Wei Fang, et al.
Published: (2023-09-01) -
Predictors of fibrogenesis in children with JIA: a single-center pilot study
by: Olga Pavlova, et al.
Published: (2024-01-01) -
Microvascularization and Expression of Fibroblast Growth Factor and Vascular Endothelial Growth Factor and Their Receptors in the Mare Oviduct
by: Pedro Pinto-Bravo, et al.
Published: (2021-04-01) -
IPF-Fibroblast Erk1/2 Activity Is Independent from microRNA Cluster 17-92 but Can Be Inhibited by Treprostinil through DUSP1
by: Sabrina Blumer, et al.
Published: (2021-10-01) -
Exploring the Spectrum of VEGF Inhibitors’ Toxicities from Systemic to Intra-Vitreal Usage in Medical Practice
by: Mariachiara Santorsola, et al.
Published: (2024-01-01)